Advances in Drug Development for Skin Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 2949
Special Issue Editor
Special Issue Information
Dear Colleagues,
Skin cancers are the most common type of cancers worldwide. While non-melanoma skin cancers (NMSC) are the most frequent, melanomas have a higher mortality rate if untreated. Although surgical treatment is often curative for skin cancer, topical and/or systemic agents are often necessary as well. The past decade has seen a rapid increase in the number and types of treatments available for treatment of skin cancers, with many more agents under development. Here, we are interested in both novel agents and treatment strategies for skin cancers (both melanomas and non-melanoma skin cancers). Articles of interest will thus span both novel agents in development and the repurposing of other agents that can be utilized towards skin cancer treatment or prevention. Of special interest are advances that deal with immune modulation for treatment of skin cancer, though studies focusing on targeted agents are also welcomed. We are interested in all aspects of drug development, from pre-clinical and in vitro studies to clinical studies, including mechanistic studies. We also welcome articles that discuss side effects from treatments for skin cancer and potential strategies to mitigate them.
Dr. Rajan P. Kulkarni
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- non-melanoma skin cancer
- squamous cell carcinoma
- basal cell carcinoma
- immunotherapies
- targeted therapies
- adverse events
- mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.